Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director · CHIEF TECHNOLOGY OFFICER | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,821,870 |
Ending reported balance
After 2026-08-18 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 7,363 · Balance 4,804,051 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-08-18 · Tax withholding · Disposed 1,778 · Balance 4,802,273 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2026-08-18 · Exercise / conversion · Acquired 5,525 · Balance 4,807,798 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2026-08-18 · Tax withholding · Disposed 1,346 · Balance 4,806,452 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2026-08-18 · Exercise / conversion · Acquired 6,162 · Balance 4,812,614 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2026-08-18 · Tax withholding · Disposed 1,501 · Balance 4,811,113 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 7 · 2026-08-18 · Exercise / conversion · Acquired 14,220 · Balance 4,825,333 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 8 · 2026-08-18 · Tax withholding · Disposed 3,463 · Balance 4,821,870 F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 17,189 |
Reported balance
After 2026-08-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-18 · Exercise / conversion · Disposed 7,363 · Balance 17,189 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 34,995 |
Reported balance
After 2026-08-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-18 · Exercise / conversion · Disposed 5,525 · Balance 34,995 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 63,688 |
Reported balance
After 2026-08-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-18 · Exercise / conversion · Disposed 6,162 · Balance 63,688 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 203,835 |
Reported balance
After 2026-08-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-18 · Exercise / conversion · Disposed 14,220 · Balance 203,835 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter.
F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter.
F6: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2023 Filed May 20, 2023 00:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,912 | $6.69 | $12,791.28 |
DisclosureSEC source: 0001209191-23-031276 · doc4.xml · nonDerivative · entry 4 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,890,258 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2023 Filed May 20, 2023 00:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 4,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031276 · doc4.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,892,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2023 Filed May 20, 2023 00:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 772 | $6.69 | $5,164.68 |
DisclosureSEC source: 0001209191-23-031276 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,887,262 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2023 Filed May 20, 2023 00:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031276 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,888,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 19, 2023 Filed Apr 20, 2023 21:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $9.71 | $194,200.00 |
DisclosureSEC source: 0001209191-23-025029 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,886,053 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $9.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 23:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $9.29 | $185,800.00 |
DisclosureSEC source: 0001209191-23-020402 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,906,053 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.14 to $9.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 00:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 117,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016984 · doc4.xml · derivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,813 Underlying: Common Stock · 117,813 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 00:59 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (Right to Buy) · Derivative | 178,062 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001209191-23-016984 · doc4.xml · derivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,062 Underlying: Common Stock · 178,062 shares Expires 2033-03-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012359 · doc4.xml · derivative · entry 4 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,123 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $10.94 | $218,800.00 |
DisclosureSEC source: 0001209191-23-012359 · doc4.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,926,053 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.79 to $11.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 772 | $10.97 | $8,468.84 |
DisclosureSEC source: 0001209191-23-012359 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,946,053 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 21, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-012359 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,946,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 897 | $13.53 | $12,136.41 |
DisclosureSEC source: 0001209191-23-008517 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,944,844 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 23:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 11 | $13.51 | $148.61 |
DisclosureSEC source: 0001209191-23-007670 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,945,741 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 23:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 1,081 | $13.50 | $14,593.50 |
DisclosureSEC source: 0001209191-23-007670 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,945,752 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 23:26 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $11.03 | $220,600.00 |
DisclosureSEC source: 0001209191-23-004327 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,946,833 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.75 to $11.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 00:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $10.38 | $207,600.00 |
DisclosureSEC source: 0001209191-22-062236 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,966,833 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 23:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $14.66 | $293,200.00 |
DisclosureSEC source: 0001209191-22-058474 · doc4.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,986,833 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.36 to $14.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 23:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058474 · doc4.xml · derivative · entry 4 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,104 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 23:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 772 | $14.75 | $11,387.00 |
DisclosureSEC source: 0001209191-22-058474 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,006,833 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 23:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-058474 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,007,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 22:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $14.42 | $288,400.00 |
DisclosureSEC source: 0001209191-22-054210 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,005,624 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.06 to $14.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 21:47 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $12.42 | $248,400.00 |
DisclosureSEC source: 0001209191-22-050770 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,025,624 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.11 to $13.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 19, 2022 Filed Aug 19, 2022 23:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $13.62 | $272,400.00 |
DisclosureSEC source: 0001209191-22-046949 · doc4.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,045,624 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046949 · doc4.xml · derivative · entry 4 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,085 Underlying: Common Stock · 1,981 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 772 | $14.06 | $10,854.32 |
DisclosureSEC source: 0001209191-22-046949 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,065,624 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,981 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046949 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,066,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 19, 2022 Filed Jul 20, 2022 22:14 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $11.83 | $236,600.00 |
DisclosureSEC source: 0001209191-22-042761 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,064,415 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.62 to $11.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 23:07 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $10.06 | $201,200.00 |
DisclosureSEC source: 0001209191-22-038768 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,084,415 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 19, 2022 Filed May 20, 2022 23:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $9.92 | $198,400.00 |
DisclosureSEC source: 0001209191-22-031172 · doc4.xml · nonDerivative · entry 3 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,104,415 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.60 to $10.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031172 · doc4.xml · derivative · entry 4 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,066 Underlying: Common Stock · 2,642 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,030 | $9.65 | $9,939.50 |
DisclosureSEC source: 0001209191-22-031172 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,124,415 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031172 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,125,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 19, 2022 Filed Apr 22, 2022 00:58 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $10.34 | $206,800.00 |
DisclosureSEC source: 0001209191-22-025251 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,122,803 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 22:03 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $11.64 | $232,800.00 |
DisclosureSEC source: 0001209191-22-020814 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,142,803 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.28 to $12.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:57 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,555 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001209191-22-017217 · doc4.xml · derivative · entry 4 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,111 Underlying: Common Stock · 10,555 shares Expires 2030-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 24, 2021; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:57 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionStock Option (Right to Buy) · Derivative | 62,456 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001209191-22-017217 · doc4.xml · derivative · entry 3 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,456 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:57 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 10,555 | $0.92 | $9,710.60 |
DisclosureSEC source: 0001209191-22-017217 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,162,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 22:57 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 62,456 | $0.25 | $15,614.00 |
DisclosureSEC source: 0001209191-22-017217 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,152,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 31,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015012 · doc4.xml · derivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,708 Underlying: Common Stock · 31,708 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:02 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 47,841 | $0.00 Strike: $13.64 | $0.00 |
DisclosureSEC source: 0001209191-22-015012 · doc4.xml · derivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,841 Underlying: Common Stock · 47,841 shares Expires 2032-02-28 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly over four years from the vesting commencement date of January 1, 2022. The option becomes fully vested on January 1, 2026. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:41 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 20,000 | $13.44 | $268,800.00 |
DisclosureSEC source: 0001209191-22-012774 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,089,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.98 to $13.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 5,294 | $15.37 | $81,368.78 |
DisclosureSEC source: 0001209191-22-009460 · doc4.xml · nonDerivative · entry 2 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.27 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 23:23 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 14,706 | $15.01 | $220,737.06 |
DisclosureSEC source: 0001209191-22-009460 · doc4.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,115,086 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.26 to $15.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 07, 2021 Filed Feb 14, 2022 23:20 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009458 · doc5.xml · nonDerivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,129,792 Read SEC document |
| July 22, 2021 Filed Jul 27, 2021 01:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048270 · doc4.xml · derivative · entry 1 Yan Ming · CIK 0001874041 · Director · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-07-22 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 22, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.